These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
709 related articles for article (PubMed ID: 32185586)
1. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Hassett MJ; Li H; Burstein HJ; Punglia RS Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586 [TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Spring L; Niemierko A; Haddad S; Yuen M; Comander A; Reynolds K; Shin J; Bahn A; Brachtel E; Specht M; Smith BL; Taghian A; Jimenez R; Peppercorn J; Isakoff SJ; Moy B; Bardia A Breast Cancer Res Treat; 2018 Dec; 172(3):733-740. PubMed ID: 30220055 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449 [TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761 [TBL] [Abstract][Full Text] [Related]
9. Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study. Falcón González A; Cruz Jurado J; Llabrés Valenti E; Urbano Cubero R; Álamo de la Gala MC; Martínez Guisado MA; Álvarez Ambite R; Rodríguez González CJ; Amérigo Góngora M; Rodríguez Pérez L; López Álvarez P; Sánchez Rovira P; González Flores E; Henao Carrasco F; Bayo Calero J; Valero Arbizu M; Quílez Cutillas A; Salvador Boffil J; Rubio Pérez E; Ruiz-Borrego M Clin Transl Oncol; 2024 Sep; 26(9):2217-2226. PubMed ID: 38538968 [TBL] [Abstract][Full Text] [Related]
10. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Squires H; Pandor A; Thokala P; Stevens JW; Kaltenthaler E; Clowes M; Coleman R; Wyld L Pharmacoeconomics; 2018 Jan; 36(1):29-38. PubMed ID: 28770452 [TBL] [Abstract][Full Text] [Related]
11. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402 [TBL] [Abstract][Full Text] [Related]
12. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Takano T; Masuda N; Ito M; Inoue K; Tanabe Y; Kawaguchi K; Yasojima H; Bando H; Nakamura R; Yamanaka T; Ishida K; Aruga T; Yanagita Y; Tokunaga E; Aogi K; Ohno S; Kasai H; Kataoka TR; Morita S; Toi M Breast Cancer Res Treat; 2024 Aug; 207(1):33-48. PubMed ID: 38767786 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Hurvitz SA; Martin M; Jung KH; Huang CS; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Fasching PA; Afenjar K; Spera G; Lopez-Valverde V; Song C; Trask P; Boulet T; Sparano JA; Symmans WF; Thompson AM; Slamon D J Clin Oncol; 2019 Sep; 37(25):2206-2216. PubMed ID: 31157583 [TBL] [Abstract][Full Text] [Related]
15. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568 [TBL] [Abstract][Full Text] [Related]
16. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. Candon D; Healy J; Crown J Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103 [TBL] [Abstract][Full Text] [Related]
17. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504 [TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Ginzac A; Molnar I; Durando X; Motte Rouge T; Petit T; D'hondt V; Campone M; Bonichon-Lamichhane N; Venat Bouvet L; Levy C; Augereau P; Pistilli B; Arsene O; Jouannaud C; Nguyen S; Cayre A; Tixier L; Mahier Ait Oukhatar C; Nabholtz JM; Penault-Llorca F; Mouret-Reynier MA Breast Cancer Res Treat; 2024 Jun; 205(2):267-279. PubMed ID: 38453781 [TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Au HJ; Eiermann W; Robert NJ; Pienkowski T; Crown J; Martin M; Pawlicki M; Chan A; Mackey J; Glaspy J; Pintér T; Liu MC; Fornander T; Sehdev S; Ferrero JM; Bée V; Santana MJ; Miller DP; Lalla D; Slamon DJ; Oncologist; 2013; 18(7):812-8. PubMed ID: 23814044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]